The National Institutes of Health has awarded The Ohio State University Center for Clinical and Translational Science (CCTS) a five-year $1.5 million grant to fund graduate student training in clinical and translational research.
Study links free radicals to heart damage caused by cancer scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.
Date Time
MedTips: Awards and Announcements
Dr. Sakima Smith has been appointed to the newly created position of chief diversity and inclusion officer at The Ohio State University Wexner Medical Center’s Heart and Vascular Center. In this new position, Smith will help shape and build a culture of diversity and inclusion at the Heart and Vascular Center. He’s also vice chair for diversity and inclusion for The Ohio State University College of Medicine’s Department of Internal Medicine and a member of both the Equity and Anti-Racism Task Force and the Diversity and Inclusion Committee at Ohio State.
Finding a way to stop chemotherapy from damaging the heart
There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.
Scientists found that this chemo drug, used to treat many types of solid tumors and blood cancers, is able to enter heart cells by hitchhiking on a specific type of protein that functions as a transporter to move a drug from the blood into heart cells.
Kevin Huang
By introducing another anti-cancer drug in advance of the chemo, the researchers were able to block the transporter protein, effectively stopping the delivery of doxorubicin to those cardiac cells. This added drug, nilotinib, has been previously found to inhibit activation of other, related transport proteins.
Finding a way to stop chemotherapy from damaging the heart
Study suggests drug intervention may prevent doxorubicin-induced cardiac injury
There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.
Scientists found that this chemo drug, used to treat many types of solid tumors and blood cancers, is able to enter heart cells by hitchhiking on a specific type of protein that functions as a transporter to move a drug from the blood into heart cells.
By introducing another anti-cancer drug in advance of the chemo, the researchers were able to block the transporter protein, effectively stopping the delivery of doxorubicin to those cardiac cells. This added drug, nilotinib, has been previously found to inhibit activation of other, related transport proteins.